Basic Information
Humira
Regulatory Information
EMEA/H/C/000481
September 8, 2003
93
March 20, 2025
Company Information
Germany
Knollstrasse 67061 Ludwigshafen
AbbVie Deutschland GmbH & Co. KG
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Please refer to the product information document.
Overview Summary
Humira is a medicine that acts on the immune system and is used to treat the following conditions: - plaque psoriasis, a disease causing red, scaly patches on the skin - psoriatic arthritis (red, scaly patches on the skin with inflammation of the joints) - rheumatoid arthritis (a disease causing inflammation of the joints) - axial spondyloarthritis (inflammation of spine causing back pain), including ankylosing spondylitis and when X-ray does not show disease but there are clear signs of inflammation - Crohn’s disease (a disease causing inflammation of the gut) - ulcerative colitis (a disease causing inflammation and ulcers in the lining of the gut) - polyarticular juvenile idiopathic arthritis and active enthesitis-related arthritis (both rare diseases causing inflammation in the joints) - hidradenitis suppurativa (acne inversa), a chronic skin disease that causes lumps, abscesses (collections of pus) and scarring on the skin - non-infectious uveitis (inflammation of the layer beneath the white of the eyeball). Humira is mostly used in adults when their conditions are severe, moderately severe or getting worse, or when patients cannot use other treatments. For detailed information on the use of Humira in all conditions, including when it can be used in children, see package leaflet or contact your doctor or pharmacist. Humira contains the active substance adalimumab.